Analysts changed outlook on top names, including SMMT, DAVA. See what others think before buying SMMT stock.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
HC Wainwright & Co. analyst Mitchell S.
Kapoor downgraded Summit Therapeutics Inc (NASDAQ:SMMT) from Buy to Neutral.
Summit Therapeutics shares closed at $17.47 on Thursday.
Wall Street analysts changed ratings on top stocks. Check out the complete list on Benzinga's analyst ratings page. AMAT was…
Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price…
Analysts change outlook on top names. Check out ratings page for upgrades, downgrades, and initiations.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN),…
UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls
Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-ratings. Considering SAIL stock?…
